Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
501-520 of 936 trials

Lutetium Lu 177 Edotreotide for Pediatric Tumors

We are studying a new targeted therapy for children with somatostatin receptor-positive tumors to find the right dose and evaluate its safety. This trial will also look at how well the treatment works compared to standard care.

RhabdomyosarcomaLymphomaNeuroendocrine Tumor>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Advanced Solid Tumors: RO7567132 and Atezolizumab Study

We are investigating the safety and effectiveness of RO7567132 alone and with Atezolizumab in patients with advanced or metastatic solid tumors. This study aims to learn how the body processes the drug and its potential benefits.

Advanced and Metastatic Solid Tumors>2 yearsSafety phase (I)Oncology

Advanced Cancers with BRAF Mutations: Sorafenib and Trametinib Study

We are testing a combination of two medications for patients with advanced-stage cancers that have BRAF mutations. The goal is to find the best dose and understand how well this treatment works and its safety.

Advanced-Stage Cancer with BRAF Mutation>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Castration-Resistant Prostate Cancer: CC-1 Antibody Study

We are testing a new bispecific antibody for patients with castration-resistant prostate cancer. The study aims to evaluate its safety and how well it may work compared to existing treatments.

Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Metastatic Renal Cell Carcinoma: Temferon Gene Therapy

We are testing a new gene therapy using modified stem cells for patients with metastatic renal cell carcinoma. The study aims to evaluate the safety and biological response to a single dose of Temferon.

Metastatic Kidney Cancer1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Reducing Radiation in PET Scans: BELOW Trial

We are studying how to lower the dose of radiopharmaceuticals used in PET scans. This research aims to ensure effective imaging while minimizing radiation exposure for patients.

Cancer>2 yearsSafety phase (I)OncologyOtolaryngology

EGL-001 for Advanced Solid Tumors

We are testing a new treatment called EGL-001 in adults with advanced or metastatic solid tumors. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced and Metastatic Solid Tumors1-2 yearsSafety phase (I)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Sage-319: Safety Study in Healthy Adults

We are testing a new medication called Sage-319 to see how safe it is and how the body handles it. This study helps us understand its effects and potential use in future treatments.

GABAergic Signaling DisordersSafety phase (I)Psychiatry

Crohn’s Disease: AZD7798 PET Study

We are examining how different doses of the drug AZD7798 are taken up in the body of patients with Crohn’s disease. This study aims to provide insights into the drug's effects on this condition.

Crohn's Disease1-2 yearsSafety phase (I)Gastroenterology

Advanced Solid Tumors: OATD-02 Treatment

We are evaluating the safety and potential effectiveness of OATD-02 in patients with advanced or metastatic solid tumors who have completed an earlier study. This research aims to understand how well this treatment works in this specific group.

Advanced Solid Tumors>2 yearsSafety phase (I)Post-Trial Drug AccessOncology

Cancer Treatment: Enhancing Radionuclide Therapy with PARP Inhibitors

We are exploring whether adding PARP inhibitors can improve outcomes for patients receiving Peptide Receptor Radionuclide Therapy for cancer. This study aims to see if the combination leads to better treatment results.

Gastroenteropancreatic Neuroendocrine Tumors>2 yearsSafety phase (I)Internal MedicineOncology

Long-Term Follow-Up of Adoptive Cell Therapies

We are monitoring individuals who received genetically modified cell treatments to check for any delayed side effects and how long these cells remain in the body. This study aims to ensure safety and understand the treatment's long-term effects.

Myxoid LiposarcomaMultiple MyelomaSynovial Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Advanced Solid Tumors: PM534 Treatment Study

We are testing a new drug called PM534 in patients with advanced solid tumors. The goal is to learn more about its safety and how it may work in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

TDP-43 Proteinopathies: New Imaging Agent Study

We are testing a new PET imaging agent to see if it can effectively identify TDP-43 inclusions in the brains of patients suspected of having related conditions. This study compares results with healthy individuals to assess its potential.

Alzheimer's DiseaseFamilial and Sporadic Amyotrophic Lateral SclerosisFamilial and Sporadic Frontotemporal DementiaSafety phase (I)NeurologyPsychiatry

Small Cell Lung Cancer: BI 764532 Dosing Study

We are testing different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. This study aims to find the most effective dose for these specific cancers.

Small Cell Lung Carcinoma>2 yearsSafety phase (I)Oncology

Healthy Volunteers Needed for New Autotaxin-Inhibitor Study

We are testing a new drug, MJK2134025, to see how it affects healthy individuals. This study will help us understand its safety and how different doses work.

StrokeSafety phase (I)AllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNeurologyOncologyOrthopedics and TraumatologyPediatricsPsychiatryPulmonologyRheumatologyUrology

Venous Ulcers: Stem Cell Treatment Study

We are testing a new treatment using adipose tissue stem cells for people with venous ulcers in their lower limbs. The study aims to see if this treatment helps wounds heal faster and improves quality of life.

Venous Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInternal Medicine